Report Overview

The global breast cancer therapeutics market was pegged at US$ 24.68 billion in 2021 and is expected to witness a CAGR of 13.80 % during the forecast period. 

Market Fundamentals 

Breast cancer is a condition in which the breast's cells proliferate out of control. Breast cancer comes in several forms. The second most common cancer in women after skin cancer is breast cancer. Over-50-year-old women are the ones most likely to be affected. Although uncommon, breast cancer can also strike men. Male breast cancer affects about 2,600 men annually in the US, accounting for less than 1% of all cases. The type of breast cancer is determined by which breast cells develop into cancer and the structure of that cells. There are three main components of a breast: connective tissue, ducts, and lobules where most commonly cancer occurs. 

[37487324]

Market Dynamics

The global breast cancer therapeutics market is mainly driven by the family history of breast cancer and owing to the high risk of breast cancer inherited by "high penetrance" gene mutations. Additionally, the increasing prevalence of breast cancer among middle-aged women, rising awareness about breast cancer, and the benefits of early diagnosis are also contributing to the growth of the global breast cancer therapeutics market. Additionally, the introduction of novel therapeutics and favorable reimbursement policies are also fueling the global breast cancer therapeutics market. However, the severe adverse effects of therapeutics and the high cost of therapeutics are holding back the growth of the global breast cancer therapeutics market. 

Market Ecosystem

The global breast cancer therapeutics market has been analyzed from four perspectives: therapy, cancer type, distribution channel, and region. 

Breast Cancer Therapeutics Market by Therapy

[8758945]

Based on therapy, the global breast cancer therapeutics market has been segmented into targeted therapy, hormonal therapy, chemotherapy, and immunotherapy. The targeted therapy segment is leading the global breast cancer therapeutics market. Breast cancer-targeted therapeutic approaches involve the use of substances or drugs that inhibit cancer growth by interrupting the function of biomolecules involved in tumor cell survival and proliferation. The large share of targeted therapy can be attributed to the increasing adoption of targeted therapies for mark-specific cancer cells which stop the growth of cancer, and have less toxicity, high specificity, and high therapeutic effect. Various regulatory bodies across the globe are taking initiatives to novel treatments to the market. For instance, in August 2022, the United States Food Drug and Administration approved the first targeted therapy for HER2 low breast cancer. This was the first therapy that has been authorized specifically for patients with the HER2-low breast cancer subtype, a newly identified subtype of HER2-negative breast cancer.

Breast Cancer Therapeutics Market by Cancer Type

Based on cancer type, the global breast cancer therapeutics market is segmented into hormone receptors, HER2+, triple negative, and others. The hormone receptors segment is leading the global breast cancer therapeutics market. The hormone receptor segment is further classified into estrogen (ER) and progesterone (PR). The growth of the market can be attributed to the high prevalence of estrogen (ER) hormone breast cancer and the introduction of novel diagnostic devices.  Nearly 80% of breast cancers are ER-positive and about 65% of these are also PR positive. However, HER2+ is also expected to show exponential growth owing to increasing cases and rising research and development.

Breast Cancer Therapeutics Market by Distribution Channels 

Based on distribution channels, the global breast cancer therapeutics market has been segmented into hospital pharmacy, retail pharmacy, and online pharmacy.  The hospital pharmacy segment is leading the global cancer therapeutics market owing to the increasing prevalence of breast cancer, and the easy availability of different therapies such as chemotherapy, targeted therapy, and hormonal therapy in hospitals. Additionally, the availability of specialty drugs and favorable reimbursement policies are also contributing to the growth of the global breast cancer therapeutics market for hospital pharmacy.

Breast Cancer Therapeutics Market by Region

Based on region, the global breast cancer therapeutics market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America dominated the global breast cancer therapeutics market. The large share of North America in the global market can be attributed to the increasing prevalence of breast cancer in the region and the rising regulatory approval of novel drugs for breast cancer treatment. Additionally, favorable reimbursement policies, developed infrastructure, and the adoption of novel technologies are also propelling the growth of the North America breast cancer therapeutics market. Nearly 287,850 new cases of invasive breast cancer and 51,400 new cases of ductal carcinoma in situ are anticipated to be diagnosed in women in the United States in 2022, according to the American Cancer Society.

Competitive Landscape

Some of the prominent players operating in the global breast cancer therapeutics market are 

• Novartis AG
• Pfizer Inc
• Oncogenex
• Apthera Inc
• Astellas 
• BioNumerik Pharmaceuticals
• Oncothyreon Inc
• Bipar Sciences
• Eli Lilly and Company 
• Novartis AG
• AstraZeneca Plc
• Sanofi 
• Merck & Co., Inc
• Bristol Myers Squibb 

Strategic Developments

• In October 2022, Accuracy and C- RAD launched automated breast cancer therapy Radixact Image-guided, intensity modulated radiation therapy system at the American Society for Radiation Oncology
• In October 2022, Novartis launched new video series for personal cancer stories campaign to create awareness about breast cancer
• In August 2022, AstraZeneca and Daiichi Sankyo received approval from USFDA for Enhertu, the first HER-2-directed therapy for patients with low metastatic breast cancer. Enhertu is an engineered HER2-directed antibody-drug conjugate (ADC) that AstraZeneca and Daiichi Sankyo are working together to develop and market

Frequently Asked Questions About This Report